Obsidian Galera merger will trade on Nasdaq as OBX, securing $350 million in private placement.
Browsing: M&A and Licensing
News and insights on mergers, acquisitions, licensing deals, and strategic collaborations across the global pharma industry.
Obsidian Galera merger results in Nasdaq listing under OBX, securing $350 million in private placement.
Lilly CrossBridge Bio deal enhances its ADC portfolio with dual-payload technology, valued at up to $300 million.
Merck Terns acquisition secures leukemia drug rights after accepting a 15% lower offer amid competition from four bidders.
Gilead Tubulis acquisition marks a strategic move to enhance its ADC technology portfolio, valued at $3.1 billion.
Neurocrine Soleno acquisition involves a $2.9 billion deal to acquire Vykat, a Prader-Willi syndrome drug with $190 million in sales.
Biogen Apellis acquisition enhances early-stage assets, boosting cash flow and strategic capacity.
Novo Nordisk partners with Vivtex in a $2.1 billion deal to enhance oral biologic drug delivery, targeting obesity treatment advancements.
Lilly CSL $100M deal involves licensing a monoclonal antibody targeting IL-6, with CSL retaining rights for end-stage kidney disease.
Madrigal RNAi drug deal involves a $4.4 billion agreement with a China-based biotech for six preclinical medicines.